This study aims to monitor the safety and efficacy of Occlutech AFR device in patients with Heart Failure.
Written, informed consent
Age ≥18 years
Presence of chronic symptomatic HF (NYHA class ≥ 2)
Left Atrial Pressure (LAP) > Right Atrial Pressure (RAP); with a gradient equal or more than 5 mmHg*
Life expectancy < 1 year, or advanced heart failure defined as ACC/AHA Stage D heart failure, or listed for heart transplantation at time of baseline visit
Severe Right Ventricular Dysfunction (TAPSE < 14 mm)
Severe Right Ventricular Dilatation (RV volume ≥ LV volume)
Severe pulmonary hypertension (PASP > 60 mm Hg)